TRT and hormone optimization: what the evidence actually supports

What's this video probably claiming?

Based on the hashtag cluster here, #trt #hormonereplacementtherapy #hormoneoptimization, this video almost certainly falls into one of the most crowded content categories on fitness TikTok: a creator discussing testosterone replacement therapy either from personal experience or as general advice to men experiencing low energy, poor libido, reduced muscle mass, or mood changes. The term "hormone optimization" is the tell. It signals this isn't just about treating diagnosed hypogonadism, it's about pushing testosterone levels to a performance ceiling. Creators in this space routinely conflate two very different populations: men with clinically confirmed hypogonadism (total testosterone below 300 ng/dL with symptoms, per Endocrine Society guidelines) and healthy men who simply want more of a good thing. Expect claims about feeling "like a different person," references to specific cypionate or enanthate protocols, and probably some dismissal of the risks involved. The views are modest at 1.1K, which suggests this is personal testimony rather than a polished sales pitch, but the hashtags do the algorithmic work regardless.

What does the science actually show?

TRT for men with confirmed hypogonadism has a legitimate evidence base. The Testosterone Trials, a coordinated set of seven placebo-controlled studies published in the New England Journal of Medicine and related journals between 2016 and 2018, enrolled 790 men aged 65 and older with low testosterone (average 234 ng/dL) and found statistically significant improvements in sexual function, walking distance, bone density, and mood after 12 months of transdermal testosterone (targeting 500 ng/dL). Effect sizes were real but modest. What those trials did not do is endorse optimization in men with normal testosterone. A 2023 meta-analysis by Corona et al. in the Journal of Sexual Medicine, pooling data from 49 RCTs, confirmed benefits for sexual dysfunction and body composition in hypogonadal men but found no meaningful benefit in eugonadal men. On the risk side, the TRAVERSE trial (Lincoff et al., 2023, NEJM) followed 5,246 men over about 33 months and found no significant increase in major cardiovascular events compared to placebo, which partially addressed the FDA's 2015 boxed warning concerns, though erythrocytosis (elevated red blood cell count) occurred in roughly 7.5% of the testosterone group versus 2.9% of controls.

Where does the social media noise diverge from clinical reality?

The optimization framing is where things get genuinely misleading. TikTok TRT content almost universally treats higher testosterone as linearly better, but that's not what the data shows. Supraphysiologic levels, anything consistently above 1000-1200 ng/dL, carry risks that creators rarely mention: erythrocytosis raising clot risk, suppression of the hypothalamic-pituitary-gonadal axis, testicular atrophy, and fertility loss that can persist after stopping. A 2021 study by Thirumalai et al. in the Journal of Clinical Endocrinology and Metabolism showed that 12 months of testosterone treatment significantly reduced sperm concentration, with some men showing azoospermia. That detail rarely makes it into the content. The other gap: creators discuss cypionate and enanthate injection protocols with the casual confidence of a pharmacist, but appropriate dosing is an individualized clinical decision requiring baseline labs, ongoing monitoring of hematocrit, PSA, and lipids, and adjustment based on trough levels. Watching a TikTok is not a substitute for that process, regardless of how relatable the creator's before-and-after story sounds.

What should you actually know?

If you're a man experiencing fatigue, low libido, or mood changes, getting a morning total testosterone level is a reasonable first step, but one lab value isn't a diagnosis. Hypogonadism requires two separate low readings plus symptoms, per both Endocrine Society and American Urological Association guidelines. Free testosterone matters too, especially in men with higher SHBG. If TRT is clinically indicated, the delivery method matters: injectable testosterone cypionate or enanthate, typically dosed every one to two weeks in clinical settings (though more frequent smaller doses are used to smooth peaks and troughs), produces different concentration profiles than gels or patches. There is no universally superior delivery method. Monitoring is non-negotiable: hematocrit at 3 and 6 months initially, PSA annually in men over 40, and lipids, because testosterone can lower HDL. The men who benefit most from TRT are those with confirmed deficiency. Men chasing optimization without a clinical basis are running an experiment on their own endocrine system with incomplete risk information.